It has been said by some that fear is the enemy of innovation. This is absolutely true about the fears being stoked by Canada’s generic drug industry and others in their misguided efforts to derail the Canada-EU Comprehensive Economic and Trade Agreement (“CETA”) negotiations because of proposed improvements to intellectual property (“IP”) standards. Estimating the extent to which EU negotiating proposals will increase Canadian health-care costs from a zero-sum perspective (i.e. an EU gain is Canada’s loss) reflects outdated trade, economic, and health policy thinking. The issue is not that Canada-EU negotiations include proposals to strengthen IP protection in Canada in the area of copyright, patents, life sciences, and elsewhere. The real problem lies more in the fact that the EU has had to make such proposals in the first place.
By Schneider Electric’s Secure Power Division - Canada
Enter your email address to
register a free account.